The Clinical Need in Liver Transplantation

Approximately 2,500 patients in the United States die every year on the liver transplant waiting list before a donor liver becomes available.1 Increasing the number of organs available for transplantation, while reducing post-transplantation complications and shortening the length of hospital stay, are important clinical goals to improve patient outcomes.

Transforming Outcomes

A controlled clinical feasibility study at Columbia University Medical Center/New York Presbyterian Hospital using a prototype LifePort Liver Transporter system found 50 percent fewer patients had biliary complications with LifePort-perfused livers. Early allograft dysfunction was seen in 25 percent of static cold stored livers compared with 5 percent of LifePort-perfused livers (p = 0.08).2 Additionally, patients receiving LifePort perfused livers had a significantly lower length of hospital stay than patients with static cold stored livers (10.9 ± 4.7 days vs. 15.3 ± 4.9 days; p = 0.006).

A second controlled study investigated hypothermic machine preservation versus static cold storage of expanded criteria livers rejected by the originating UNOS region.3 During 12-months post transplantation there were significantly fewer biliary complications in the perfused group (4 vs. 13, respectively; p = 0.016), and early allograft dysfunction rates were also lower (19% vs. 30%). Mean hospital stay was also significantly shorter in the perfused group (13.6 vs. 21.1 days). The results suggest that hypothermic machine perfusion (HMP) of livers is safe and allows for transplantation of expanded criteria livers deemed untransplantable by multiple centers. Study investigators concluded that HMP has the potential to increase the donor pool and the availability of livers for patients on the waiting list.

LifePort Liver Transporter is in the process of securing US and European regulatory registrations. Its design, engineering and performance capabilities are based upon the LifePort prototype system used in the Columbia University Medical Center/ New York Presbyterian Hospital, and the proven technology platform of the market leading LifePort Kidney Transporter.

Innovative LifePort technology

LifePort Liver Transporter is designed to deliver precision controlled perfusion of the hepatic artery and portal vein. Hypothermic perfusion is supported by redundant preservation systems for safety – dynamic perfusion plus static cold storage.

Key Features

Programmable display

The clear programmable interface displays key data that track real-time organ perfusion status, patient ID number and blood type, cross clamp and total infusion time, perfusate temperature, hepatic and portal flow and pressure and total flow.

Fold-out work surfaces

LifePort Liver Transporter's lid folds out to provide an optional work surface for crowded OR suites. The work surfaces lids are hinged for easy removal and storage.

Optional custom adjustable cart

The height-adjustable fold-flat cart seamlessly docks with LifePort Liver Transporter, and is designed to provide optimal surgeon comfort and optical range.

LifePort Liver Transporter - Clinical Experience

Clinical experience of LifePort Liver Transporter

Watch Dr. James V. Guarrera, Associate Professor of Surgery, Surgical Director of Adult Liver Transplantation, Columbia University Medical Center/New York Presbyterian Hospital, NY, USA, discuss his experience with hypothermic machine perfusion of livers for clinical transplantation

Full Summary of the Clinical Experience for LifePort Liver Transporter ›

Caution—Investigational Device. Limited by Federal law to investigational use. Registrations underway in US and EU.

 

 

References
1. OPTN/SRTR 2011 Annual Data Report: liver
http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/03_%20liver_12.pdf. Accessed June 2014.
2. Guarrera JV, et al. Am J Transpl 2010;10:372–81.
3. Guarrera JV, et al. Am J Transpl 2015;15(1):161–9.

Machine perfusion of the liver has now become a clinical reality. The new portable LifePort Liver Transporter from Organ Recovery Systems will enable initiation of HMP at the donor recovery site, which will further reduce preservation-related allograft damage. In our studies, HMP resulted in fewer complications, reduction in biliary strictures and shorter hospital length of stay as well as early allograft dysfunction.